H-Shaped PEG Derivative for High Drug Loading and Low Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional branched polyethylene glycol derivatives with a single active group result in low drug loading and limited applications, and pegylated drugs often experience reduced activity and severe toxic side effects due to steric effects and improper tissue distribution.
Innovation Solution
Development of an H-shaped multifunctionalized polyethylene glycol compound with a linear main chain and four branch chains, allowing for adjustable molecular weight, increased active groups, and degradable linkages to enhance drug loading and tissue distribution, while reducing immunogenicity and toxic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional branched polyethylene glycol with single active group is used, then structure is simple, but drug loading is low
Solution Approach 1:
The patent creates a multifunctionalized polyethylene glycol core with multiple active groups (carboxyl, hydroxyl, amino groups) that can simultaneously bind multiple drug molecules or different types of molecules (drugs, targeting ligands, imaging agents), transforming the single-function conventional PEG into a multi-functional platform for enhanced drug loading capacity
Solution Approach 2:
The patent divides the polyethylene glycol structure into a core segment and multiple branch segments, where the core contains multiple active groups and each branch can independently carry drug molecules. This segmentation allows multiple drug molecules to be loaded on a single PEG molecule, significantly increasing drug loading capacity while maintaining structural organization
2Duration of action of moving object
If pegylation is performed to increase circulation time, then half-life is prolonged, but drug activity decreases due to steric effects
Solution Approach 1:
The patent applies different types of polyethylene glycol chains (varying in molecular weight, hydrophilicity, and flexibility) to different locations on the drug molecule. By optimizing the local PEG structure at the drug binding site versus the circulation interface, the patent maintains drug activity at the target site while providing protective coverage for circulation stability
Solution Approach 2:
The patent introduces flexible linkers and adjustable PEG chain lengths that allow the PEG-drug conjugate to dynamically adapt its conformation. The flexible structure enables the drug to maintain its active configuration when bound to the target while extending protective PEG chains in the circulation environment, thus preserving both activity and circulation time
3Object-affected harmful factors
If conventional PEGylation is used to reduce toxic side effects, then some protection is provided, but biosafety requirements for anticancer drugs cannot be satisfied
Solution Approach 1:
The patent systematically varies critical parameters including PEG molecular weight, branch chain length, core structure composition, and active group type to optimize the balance between protective effects and biosafety. By adjusting these parameters, the patent achieves enhanced reduction of toxic side effects while meeting stringent biosafety requirements for anticancer therapies
Solution Approach 2:
The patent creates composite PEG structures combining multiple functional components (different PEG chain types, flexible linkers, degradable bonds, targeting ligands) into an integrated system. This composite approach provides multi-layered protection against toxic effects while enabling targeted delivery that further reduces off-target toxicity, satisfying high biosafety standards
4Quantity of substance
If H-shaped multifunctionalized PEG with multiple active groups is used, then drug loading increases, but molecular structure complexity increases
Solution Approach 1:
The patent divides the polyethylene glycol structure into a core segment and multiple branch segments, where the core contains multiple active groups and each branch can independently carry drug molecules. This segmentation allows multiple drug molecules to be loaded on a single PEG molecule, significantly increasing drug loading capacity while maintaining structural organization
Solution Approach 2:
The patent creates a multifunctionalized polyethylene glycol core with multiple active groups (carboxyl, hydroxyl, amino groups) that can simultaneously bind multiple drug molecules or different types of molecules (drugs, targeting ligands, imaging agents), transforming the single-function conventional PEG into a multi-functional platform for enhanced drug loading capacity
Data Source
AI summary
Disclosed are a multifunctionalized polyethylene glycol derivative and a preparation method therefor. The derivative has an H-shaped structure as represented by formula (1) and comprises one linear core LPEG and four PEG branch chains, where n1, n2, n3, and n4 respectively are the degrees of polymerization of the branch chains, U1 and U2 are trivalent branching groups connecting the core LPEG to two of the PEG branch chains, F1 and F2 contain a functional group or a protected form R01 thereof and may or may not contain a branched group G, correspondingly, the number of R01 is one or more, F1 and F2 are either identical or different, any one linking group in the molecule or any linking group formed with an adjacent heteroatom group can either remain stable or be degraded, and any one PEG segment in the molecule is discretely polydispersed or monodispersed. The multifunctional polyethylene glycol is flexible and diverse in terms of branch structures and the lengths of branching arms, has various parameters and performance indicators that are adjustable and easy to control, and has a broad applicability.